Privium Fund Management B.V. Sells 2,754 Shares of uniQure (NASDAQ:QURE)

Privium Fund Management B.V. decreased its stake in uniQure (NASDAQ:QURE) by 0.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 742,162 shares of the biotechnology company’s stock after selling 2,754 shares during the quarter. uniQure makes up about 3.0% of Privium Fund Management B.V.’s holdings, making the stock its 8th biggest position. Privium Fund Management B.V. owned approximately 1.52% of uniQure worth $13,107,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Franklin Resources Inc. purchased a new stake in shares of uniQure during the third quarter worth $7,360,000. Point72 Asset Management L.P. raised its stake in shares of uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after purchasing an additional 752,889 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of uniQure by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after buying an additional 6,362 shares during the last quarter. FMR LLC grew its stake in shares of uniQure by 8,056.6% in the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after buying an additional 346,274 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in uniQure by 6.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 277,275 shares of the biotechnology company’s stock worth $1,367,000 after buying an additional 16,464 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Price Performance

NASDAQ QURE opened at $13.31 on Wednesday. The stock has a market capitalization of $719.76 million, a PE ratio of -2.68 and a beta of 0.36. The stock has a 50-day simple moving average of $13.86 and a 200 day simple moving average of $10.36. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18.

Analyst Ratings Changes

QURE has been the subject of several recent research reports. Guggenheim reissued a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Leerink Partners upped their price objective on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. The Goldman Sachs Group raised their target price on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of uniQure in a research report on Tuesday, March 4th. Finally, Cantor Fitzgerald increased their price objective on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $38.89.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 26,727 shares of the stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total value of $285,978.90. Following the completion of the sale, the chief executive officer now owns 571,188 shares in the company, valued at approximately $6,111,711.60. This trade represents a 4.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Christian Klemt sold 10,438 shares of the business’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $107,407.02. Following the transaction, the chief financial officer now owns 217,730 shares in the company, valued at $2,240,441.70. This represents a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock worth $961,401 over the last three months. 4.74% of the stock is currently owned by insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.